2022 World Conference on Lung Cancer (ePosters)-EP08.01-045. The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumor Mutation Burden and Survival

EP08.01-045. The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumor Mutation Burden and Survival

Back to course

Pdf Summary

This study aimed to assess the impact of smoking status at the initiation of immune checkpoint inhibitor (ICI) therapy on tumor mutation burden (TMB) and overall survival. The study was conducted on veterans with advanced non-small cell lung cancer (NSCLC) who initiated first-line ICI therapy between January 2019 and December 2021.<br /><br />The results showed that current smokers at the time of ICI initiation tended to have lung cancers with higher TMB values compared to former smokers. TMB was found to be predictive of overall survival on ICI therapy in both current and former smokers. However, there was no statistically significant interaction between smoking status and TMB for overall survival.<br /><br />The study used a retrospective, multi-center design and collected data from the nationwide US Veterans Affairs healthcare system. The data sources included the VA National Precision Oncology database and the VA Corporate Data Warehouse. The study included patients who had TMB measured within 3 months of ICI initiation and were either current or former smokers.<br /><br />The statistical analysis used multivariable logistic regression, Student's t-test, and Kaplan-Meier analysis. Multivariable Cox regression was also employed to identify any significant interaction between smoking status and TMB on overall survival.<br /><br />The study acknowledges that its observational design may not fully account for unmeasured confounders that could affect overall mortality among current and former smokers.<br /><br />In conclusion, this study found that smoking status at the time of ICI initiation had an impact on TMB and overall survival. Current smokers tended to have higher TMB values, and TMB was predictive of overall survival in both current and former smokers. However, there was no significant interaction between smoking status and TMB for overall survival on ICI therapy.

Asset Subtitle

Julie T. Wu

Meta Tag

Speaker Julie T. Wu

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

smoking status

immune checkpoint inhibitor therapy

tumor mutation burden

overall survival

non-small cell lung cancer

retrospective study

multivariable logistic regression

Kaplan-Meier analysis

US Veterans Affairs healthcare system

observational design